In other cancers, Dasatinib is capable of impeding cell migration and invasion through the inhibition of SRC, which blocks the transmission of downstream signals to proteins like focal adhesion kinase (FAK), responsible for adhesion, as well as MAPK and p27, which are involved in regulating the cell cycle (Johnson et al., 2005; Nam et al., 2005). Here, SRC is linked to cancer.